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Abstract 
Purpose 
Perianal Crohn’s disease (CD) encompasses a variety of lesion similar to luminal disease, 
which are usually not distinctly assessed. Links between luminal and perianal CD phenotype 
remains therefore underreported, and we aimed to describe both luminal and perianal 
phenotype and their relationships. 
Methods 
From January 2007, clinical data of all consecutive patients with CD seen in a referral center 
were prospectively recorded. Data recorded until October 2011 were extracted and reviewed 
for study proposal. 
Results 
A total of 282 patients (M/F, 108/174; aged 37.8 ± 16.2 years) were assessed that included 
154 cases (54.6 %) with anal ulceration, 118 cases (41.8 %) with fistula, 49 cases (17.4 %) 
with stricture, and 94 cases without anal lesion (33.3 %). Anal ulcerations were associated 
with fistulas (N = 87/154) in more than half of patients (56.5 %) and were isolated in 55 
patients (35.7 %). Most of strictures (94 %) were associated with other lesions (N = 46/49). 
Harvey-Bradshaw score was significantly higher in patients with ulcerations (p < 0.001) as 
compared to those with perianal fistulas (p = 0.15) or with anal strictures (p  = 0.16). 
Proportions of complicated behavior (fistulizing or stricturing) of luminal CD were similar 
according to anal lesions: anal fistulas were not significantly associated to penetrating 
Montreal phenotype (N = 4/31 p = 0.13) as well as anal stricture and stricturing Montreal 
phenotype (N = 3/49, p = 0.53). 
Conclusions 
The phenotype of luminal disease does not link with the occurrence and the phenotype of 
perianal Crohn’s disease. Anal ulcerations denote a more severe disease on both luminal and 
perianal locations and should consequently be taking into account in physician decision-
making. 
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Introduction 
In spite of their frequency, perianal lesions were not mentioned as a feature of Crohn’s 
disease (CD) in the initial description and were only recognized as such 30 years later [1]. 
Perianal Crohn’s disease (PCD) encompasses fistulizing lesions including perianal fistulas 
and abscesses and non-fistulizing lesions such as ulcerations, strictures, or skin tags [2–4]. 
PCD is one of the most dreaded complications of CD leading to anal pain, discharge, 
dyschezia, and fecal incontinence in addition to emotional symptoms and impairment of 
social and sexual functioning that significantly alter the quality of life of patients [4, 5]. 
Moreover, PCD independently denotes a more aggressive and disabling CD phenotype [6, 7]. 
According to European guidelines, use of the Montreal classification is advocated in order to 
better define and treat CD [8]. In this classification, PCD is summarized to a “p” whereas 
prognosis and significance may vary according to the type of perianal lesions. Both 
physicians and surgeons are aware of anal fistulas and abscesses. In contrast, anal strictures, 
ulcers, and anal phenotypes are underreported in both studies and guidelines and consequently 
are not taken into account in prognosis and treatment strategies despite an easy access to their 
diagnosis. 
It remains unclear whether fistulizing or non-fistulizing or both PCD behaviors affect overall 
disease outcomes. The aim of the study was therefore to describe both luminal and perianal 
phenotypes in a prospective cohort of subjects suffering from Crohn’s disease as well as 
relationship between the two localizations. 
Methods 
Study population 
All hospital records of consecutive patients suffering from CD, followed in a French referral 
center for inflammatory bowel disease and proctology, University Hospitals of Rennes, 
France, between January 2007 and October 2011, were reviewed. All patients with an 
established diagnosis of CD based on clinical, biological, radiological, endoscopic, and/or 
histological evidence were prospectively enrolled in a registry and followed up. 
The following data were prospectively recorded in a secure database: sex, age, size, weight, 
CD phenotype according to the Montreal classification [9], and treatment (including steroids, 
5-ASA, immunosuppressives, TNF antagonists, and miscellaneous treatment). 
At each clinic and for each patient, CD activity was evaluated by using the Harvey-Bradshaw 
score [10], anatomical classification of PCD was described according to the Cardiff 
classification (including a digital examination) [11], and PCD activity was evaluated with the 
Perianal Disease Activity Index (PDAI) [12]. 
To supplement data from the registry for study purpose, the following clinical data were 
extracted from chart review of patients: age at diagnosis, Montreal CD classification at 
diagnosis, previous medications, and history of abdominal and anal surgery. 
According to Harvey-Bradshaw score (HBS), CD was considered in clinical remission when 
HBS was below 4, mild to moderately active when HBS ranged from 4 to 12, and severely 
active with a HBS above 12. 
Although elementary PCD lesions are usually described separately, they are often associated 
at an individual level. Anal strictures were mostly associated to other PCD lesions (e.g., 
ulceration and/or fistula) and were not separately analyzed. Thus, the population of the study 
was separated into four groups based on their anal phenotype: 
 Ulceration phenotype: anal ulceration without fistula 
 Mixed phenotype: anal ulceration associated with fistula 
 Fistula phenotype: fistula without anal ulceration 
 Control group: neither ulceration, nor fistula 
Statistical analysis 
Quantitative variables were described as mean ± standard deviation (SD). All analysis and 
data were performed on the patient at the time of their first management in our center. 
Categorical variables were presented as counts and percent of the cohort. The non-parametric 
Wilcoxon signed-rank test for continuous variable and the non-parametric Pearson test for 
categorical variable were used to compare disease characteristics according to elementary 
PCD lesions and according to anal phenotype. Statistical analyses were performed using 
JMP® Pro 9.0.2 software. 
Ethical considerations 
The study was approved by the Hospital Ethics Committee and the “Commission Nationale 
Informatique et Liberté” (CNIL n°1412467). 
Results 
Characteristics of the population 
Data of 282 consecutive CD patients (M/F, 108/174, aged 37.8 ± 16.2 years) were 
prospectively recorded during the study period: 154 patients (54.6 %) had anal ulceration 
(superficial ulcer U1, 77; cavitating ulcer U2, 77), 118 patients (41.8 %) had fistula 
(superficial fistula F1, 33; high and/or complex fistula F2, 85), 49 patients (17.4 %) had 
stricture (short stricture S1, 32; long stricture S2, 17), and 94 patients had no PCD (33.3 %). 
The mean duration of CD was 8.2 ± 7.3 years, and the mean duration of anal symptoms was 
1.8 ± 3.2 years. Previous anal surgery for fistulas was performed in 110 patients (39 %). Ileal 
resections (N = 21; 7.5 %), ileocolectomy (N = 38; 13.5 %), partial colectomy (N = 5; 2.5 %), 
and total colectomy (N  = 12; 4.3 %) were previously reported in 76 patients (26.6 %). Anti-
TNF treatment has been instituted in 183 patients (64.9 %), for a mean duration of 
2.1 ± 2.8 years: 122 (43.3 %), 43 (15.2 %), and 18 (6.3 %) subjects before, during, and after 
referral, respectively. In fact, 102 patients had previous biologics at referral and 75 underwent 
an intestinal resection at referral. This may bias the analysis. Infliximab was the most often 
used biologics (N = 109; 59.6 %) compared with adalimumab (N = 44; 24 %). 
Thiopurines and methotrexate were used in 148 (52.4 %) and 34 (12.1 %) patients, 
respectively. Regarding luminal CD, 127 patients (45 %) were in remission according to the 
HBS (<4), 118 patients (41.9 %) had mild to moderate disease activity (HBS score from 4 to 
12), and 37 patients (13.1 %) suffered from severe active disease (HBS >12). 
Elementary anal lesions 
Figure 1 shows associations of elementary fistulizing and non-fistulizing anal lesions in CD. 
Anal ulcerations were associated with fistulas (N = 87/154) in more than half of the cases 
(56.5 %) and were isolated (N = 55/154) in one third (35.7 %) of patients. Strictures were 
mainly (94 %) associated with other lesions (N = 46/49). Above 188 patients who experienced 
PCD, 14.9 % (N  = 28/188) had an association of ulceration, fistula, and stricture. As 
expected, PDAI index significantly increased with the severity of anal ulcerations (U0, 
0.8 ± 2.4; U1, 6.4 ± 4.7; U2, 9.7 ± 4.8; p < 0.001), fistulas (F0, 2.6 ± 4.1; F1, 7.2 ± 4.7; F2, 




Fig. 1  
Distribution of perianal lesions in the population study, according to Cardiff classification 
(UFS ulceration-fistula-stricture) 
Patients with anal ulceration had a shorter CD disease duration as compared to those without 
ulceration (U0, 9.4 ± 7.5; U1, 7.9 ± 6.9; U2, 6.5 ± 6.8 years; p < 0.001). 
Overall CD characteristics according to perianal lesions 
Regarding elementary lesion, the body mass index (BMI) was lower in the presence of 
ulceration (U0, 24.9 ± 5.9; U1, 21.3 ± 4.2; U2, 21.9 ± 4; p < 0.001). Such differences were not 
encountered in patients with fistulas (F0, 23.4 ± 5.3; F1, 22.7 ± 4.7; F2, 21.9 ± 4.3; p = 0.29) or 
those with strictures (S0, 23.1 ± 5.3; S1, 21.5 ± 3.7; S2, 22.1 ± 4.2; p  = 0.29). Harvey-
Bradshaw score was significantly higher in patients with ulcerations (U0, 3.7 ± 3.5; U1, 
6.6 ± 4.7; U2, 8.0 ± 5.2; p < 0.001). Such differences were not encountered in patients with 
fistulas (F0, 5.3 ± 4.7; F1, 6.7 ± 5.1; F2, 5.8 ± 4.5; p = 0.15) or those with strictures (S0, 
5.4 ± 4.8; S1, 6.3 ± 4.2; S2, 8.9 ± 5.1; p = 0.16). 
Anal phenotypes 
The baseline characteristics of the population according to their main anal phenotype are 
listed in Table 1. Again, Montreal phenotypes of luminal disease at diagnosis were not 
significantly different between the various phenotypes of PCD. Fistula or mixed statuses were 
not significantly associated to penetrating Montreal phenotype (B3) (N = 4/31 and N = 16/87, 
respectively, p = 0.13). No association was found between anal stricture and stricturing 
Montreal phenotype (B2) (N = 3/49, p = 0.53). No anatomical association was found between 
the anal and the luminal location phenotype (L phenotype; p  = 0.37). As compared to fistula 
phenotype and control groups, both ulceration and mixed phenotypes had a more severe 
luminal activity, as highlighted by a higher Harvey-Bradshaw score and a lower body mass 
index. As compared to fistula phenotype, these two groups had also a more severe anal 
disease as assessed by PDAI and biologics were more frequently used. Finally, the prevalence 
of stricture was significantly higher in those with mixed anal lesions. 
Table 1  
Baseline characteristics of the population according to anal phenotype 
Anal phenotype 










Mean age (years) (m ± SD) 35 ± 17 34.3 ± 16 39.3 ± 12 40.1 ± 2 <0.05 
Disease duration (m) (m ± SD) 97 ± 99 90 ± 98 145 ± 120 115 ± 90 <0.05 
Body mass index (kg/m2) 
(m ± SD) 21.6 ± 3.8 21.6 ± 4.3 24.3 ± 4.3 25.1 ± 6.3 0.001 
Montreal classification at diagnosis, n (%) 
 9 (13.4) 14 (16.1) 4 (12.9) 10 (10.3)  
 57 (85.1) 65 (74.7) 21 (67.7) 71 (73.2)  
 7 (8.9) 9 (10.3) 1 (3.2) 15 (15.4)  
 7 (8.9) 5 (5.7) 2 (6.4) 7 (7.2)  
Treatments, n (%) 
No anti-TNF  13 (19.4) 23 (26.4) 11 (35.5) 52 (53.6) 0.0001
Anti-TNF initiation  
Previous/current/after  
26/18/10 38/21/5 18/1/1 40/3/2 0.0001
Prior intestinal resection  10 (14.9) 19 (21.8) 15 (48.4) 31 (31.9) 0.002 
Luminal disease activity 
Liquid stool frequency 
(m ± SD)  3.3 ± 3.4 3 ± 3.1 1.3 ± 2 1.9 ± 2.9  
Harvey-Bradshaw score (HBS) 7.4 ± 5.3 7.1 ± 4.8 3.1 ± 2.9 3.9 ± 3.7 0.001 
Anal phenotype 










at inclusion (m ± SD)  
HBS  <4, n (%) 20 (29.8) 25 (28.7) 23 (74.2) 59 (60.8) 0.0001
HBS [4–12],  n (%) 34 (50.7) 46 (52.9) 1 (3.2) 33 (34) 0.0001
HBS  >12, n (%) 13 (19.5) 16 (18.4) 7 (22.6) 5 (5.2) 0.0001
Anal disease activity 
PDAI (m ± SD)  6.1 ± 4.4 9.5 ± 5 2.9 ± 3.6  0.001 
Anal stricture,  n (%) 12(17.9) 28 (32.1) 6 (19.4) 3 (3.1) 0.001 
CD Crohn’s disease, PCD perianal Crohn’s disease, A1 age at diagnosis below 16 years, B1 
non-stricturing non-penetrating behavior, L1 ileal location, L4 isolated upper disease location, 
HBS Harvey-Bradshaw score, TNF tumor necrosis factor, PDAI Perianal Disease Activity 
Index 
Discussion 
Patients of this prospectively recorded database were assessed using recommended 
classifications and validated scales [8, 13]. Both fistula and non-fistula lesions of PCD were 
carefully recorded with an equal interest. Similarly to the Montreal classification of the 
luminal disease, different anal phenotypes have been described. The main strengths are the 
duration of follow-up (about 5 years), the management of patients with a standardized 
monitoring using validated scales, and the prospective assessment. However, this 
retrospective study has several limitations. Proctitis was not recorded in the database, and 
consequently, the impact of active proctitis could not be assessed. Because this study was 
performed in a tertiary referral center, the effects of TNFα antagonists remain difficult to 
interpret because of the large number of patients treated with TNFα prior to and after the 
diagnosis of anoperineal lesions. The classifications were obtained from the first physical 
examination in the referral center. Thus, some patients had a previous history of anti TNF 
medication and/or intestinal resection. In fact, 102 patients had previous biologics at referral 
and 75 underwent an intestinal resection at referral. This may bias the analysis. 
The high prevalence of anal lesions in accordance with previous reported experience of 
fistulas may not only be related to this careful assessment but it also reflects the recruitment 
of a tertiary center [6, 14, 15]. Thus, the systematic prospective recording of elementary 
lesions and their associations are the key points rather than the incidence of anal lesions. 
In fact, anal ulcerations were more frequent than previously reported [6, 14, 16–21]. This 
result suggests that anal ulcerations could be underdiagnosed because of the lack of perianal 
assessment during follow-up of patients. Given the impact of PCD lesions, practitioners 
should pay particular attention to the occurrence of anal ulceration since it may represent a 
clinical marker of an active Crohn’s disease. In the present study, patients with anal 
ulcerations had higher symptomatic scores in the assessment of both anal (PDAI) and luminal 
(Harvey-Bradshaw score, BMI) activity of Crohn’s disease. This may represent a non-
invasive marker of follow-up which may be prospectively tested in patients with anal 
ulcerations. Biologics are currently more used in this group. This concept was pointed out 
before the era of biologics in another cohort of anal lesion of CD [6]. From a clinical point of 
view, biologics may be used to treat anal ulceration but an evaluation of such a therapeutic 
strategy cannot be recommended without a prospective randomized evaluation which is 
lacking. 
In fact, patients with anal fistulas did not show any similar association with luminal activity 
since Harvey-Bradshaw scores did not significantly differ as compared to those with no anal 
lesion. In contrast to anal ulceration, biologics are recommended to treat drained fistulas with 
a better level of evidence [22]. 
Although anal and luminal phenotype share similar anatomical classification, we did not find 
any link between them in the present series. There was no significant association between the 
occurrence of perianal fistula or anal stricture and B2 or B3 Montreal phenotype. From a 
clinical point of view, this lack of association is important and the physician cannot consider a 
B2 phenotype in a patient with an anal fistula. We can speculate that the natural history of 
internal fistulas is different from that of anal fistulas. 
A significant association between PCD and intestinal fistulas was reported in a previous series 
[23]. Ileal disease was identified as predictive factor of perianal surgery elsewhere [24]. 
However, the nature of the anal lesions was not detailed in these two experiences. 
Of note, PCD fistulas carried a higher risk of anal stricture. No significant association has 
been observed between anal stenosis and disease activity (data not shown). Anal stricture does 
not remain a healing scare with non-reversible consequence since it is associated to 
inflammatory processes such as ulceration and fistulas. In fact, biologics may improve and 
reverse this condition [25]. 
In conclusion, our results indicate that the phenotype of luminal disease does not link with the 
occurrence and the type of anal lesion of CD. For this reason, it is reasonable to add a specific 
description of anal phenotype to the Montreal classification. The main reason is that anal 
ulcerations carry a pertinent clinical impact of a more severe disease on both luminal and 
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